CLINICAL_TRIALS
trial_result
· 2020-03-19
Clinical Trial Update: A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. [Phase 2]
Summary
A Phase 2 pilot study evaluating CC-220 (lenalidomide analog) for treating systemic lupus erythematosus has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2020-03-19